BRPI0907898B8 - antagonistas do receptor da melanocortina-5 3-substituído-1, 4-diazepan-2-ona - Google Patents
antagonistas do receptor da melanocortina-5 3-substituído-1, 4-diazepan-2-onaInfo
- Publication number
- BRPI0907898B8 BRPI0907898B8 BRPI0907898A BRPI0907898A BRPI0907898B8 BR PI0907898 B8 BRPI0907898 B8 BR PI0907898B8 BR PI0907898 A BRPI0907898 A BR PI0907898A BR PI0907898 A BRPI0907898 A BR PI0907898A BR PI0907898 B8 BRPI0907898 B8 BR PI0907898B8
- Authority
- BR
- Brazil
- Prior art keywords
- melanocortin
- diazepan
- substituted
- receptor antagonists
- formula
- Prior art date
Links
- 102000030612 Melanocortin 5 receptor Human genes 0.000 title abstract 2
- 108010088565 Melanocortin 5 receptor Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- -1 3-substituted-1, 4-diazepan-2-one Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010039792 Seborrhoea Diseases 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3289808P | 2008-02-29 | 2008-02-29 | |
| US61/032,898 | 2008-02-29 | ||
| PCT/AU2009/000232 WO2009105825A1 (en) | 2008-02-29 | 2009-02-27 | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0907898A2 BRPI0907898A2 (pt) | 2018-05-22 |
| BRPI0907898B1 BRPI0907898B1 (pt) | 2020-09-29 |
| BRPI0907898B8 true BRPI0907898B8 (pt) | 2021-05-25 |
Family
ID=41015442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907898A BRPI0907898B8 (pt) | 2008-02-29 | 2009-02-27 | antagonistas do receptor da melanocortina-5 3-substituído-1, 4-diazepan-2-ona |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8440653B2 (enExample) |
| EP (1) | EP2257533B1 (enExample) |
| JP (1) | JP5503559B2 (enExample) |
| KR (1) | KR101620116B1 (enExample) |
| CN (1) | CN102007106B (enExample) |
| AU (1) | AU2009219108B2 (enExample) |
| BR (1) | BRPI0907898B8 (enExample) |
| CA (1) | CA2716256C (enExample) |
| ES (1) | ES2439964T3 (enExample) |
| IL (1) | IL207701A (enExample) |
| MX (1) | MX2010009486A (enExample) |
| NZ (1) | NZ587362A (enExample) |
| RU (1) | RU2524245C2 (enExample) |
| WO (1) | WO2009105825A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5503558B2 (ja) * | 2008-02-29 | 2014-05-28 | ミメチカ ピーティーワイ エルティーディー | Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療 |
| WO2016149628A1 (en) * | 2015-03-19 | 2016-09-22 | Chembridge Corporation | Tgr5 agonists |
| US11485725B2 (en) | 2017-12-15 | 2022-11-01 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
| CN116262115A (zh) * | 2021-12-15 | 2023-06-16 | 深圳先进技术研究院 | 释放氨基酸及其衍生物类药物的医用材料及其应用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP254898A0 (en) * | 1998-03-24 | 1998-04-23 | University Of Queensland, The | Peptide turn mimetics |
| PL204753B1 (pl) * | 2000-05-25 | 2010-02-26 | Hoffmann La Roche | Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie |
| EP1425029A4 (en) * | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
| US6916812B2 (en) | 2001-10-09 | 2005-07-12 | Bristol-Myers Squibb Company | Alpha-aminoamide derivatives as melanocortin agonists |
| AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
| WO2008017852A1 (en) | 2006-08-11 | 2008-02-14 | Palatin Technologies, Inc. | Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators |
| JP5503558B2 (ja) * | 2008-02-29 | 2014-05-28 | ミメチカ ピーティーワイ エルティーディー | Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療 |
-
2009
- 2009-02-27 EP EP09716109.5A patent/EP2257533B1/en not_active Not-in-force
- 2009-02-27 US US12/919,973 patent/US8440653B2/en not_active Expired - Fee Related
- 2009-02-27 AU AU2009219108A patent/AU2009219108B2/en not_active Ceased
- 2009-02-27 CA CA2716256A patent/CA2716256C/en not_active Expired - Fee Related
- 2009-02-27 NZ NZ587362A patent/NZ587362A/en not_active IP Right Cessation
- 2009-02-27 ES ES09716109.5T patent/ES2439964T3/es active Active
- 2009-02-27 RU RU2010137033/04A patent/RU2524245C2/ru active
- 2009-02-27 JP JP2010547919A patent/JP5503559B2/ja not_active Expired - Fee Related
- 2009-02-27 WO PCT/AU2009/000232 patent/WO2009105825A1/en not_active Ceased
- 2009-02-27 MX MX2010009486A patent/MX2010009486A/es active IP Right Grant
- 2009-02-27 BR BRPI0907898A patent/BRPI0907898B8/pt not_active IP Right Cessation
- 2009-02-27 CN CN200980113158.7A patent/CN102007106B/zh not_active Expired - Fee Related
- 2009-02-27 KR KR1020107021385A patent/KR101620116B1/ko not_active Expired - Fee Related
-
2010
- 2010-08-19 IL IL207701A patent/IL207701A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010137033A (ru) | 2012-04-10 |
| AU2009219108A1 (en) | 2009-09-03 |
| WO2009105825A1 (en) | 2009-09-03 |
| EP2257533B1 (en) | 2013-09-18 |
| CA2716256C (en) | 2016-08-23 |
| AU2009219108B2 (en) | 2013-11-21 |
| KR20100126440A (ko) | 2010-12-01 |
| BRPI0907898A2 (pt) | 2018-05-22 |
| RU2524245C2 (ru) | 2014-07-27 |
| ES2439964T3 (es) | 2014-01-27 |
| BRPI0907898B1 (pt) | 2020-09-29 |
| HK1149255A1 (en) | 2011-09-30 |
| JP2011514339A (ja) | 2011-05-06 |
| IL207701A (en) | 2017-04-30 |
| EP2257533A1 (en) | 2010-12-08 |
| EP2257533A4 (en) | 2011-05-11 |
| US20110059952A1 (en) | 2011-03-10 |
| NZ587362A (en) | 2012-06-29 |
| JP5503559B2 (ja) | 2014-05-28 |
| US8440653B2 (en) | 2013-05-14 |
| CN102007106B (zh) | 2014-09-03 |
| CN102007106A (zh) | 2011-04-06 |
| MX2010009486A (es) | 2011-02-22 |
| IL207701A0 (en) | 2010-12-30 |
| CA2716256A1 (en) | 2009-09-03 |
| KR101620116B1 (ko) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
| MX380755B (es) | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). | |
| MX2010004857A (es) | Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel. | |
| JO2872B1 (en) | New vehicles | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| ATE542531T1 (de) | Nitrofuran-verbindungen zur behandlung von krebs und angiogenese | |
| BR112015028879A2 (pt) | derivados heterocíclicos | |
| EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| NO20092444L (no) | Heteroarylamidderivater | |
| CR20110658A (es) | Antagonistas de la trayectoria hedgehog de ftalazina desustituida | |
| DE602007010781D1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
| ATE445624T1 (de) | Verbindungen und zusammensetzungen als ppar- modulatoren | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| BRPI0514736A (pt) | inibidores do receptor sigma | |
| BRPI1013777A8 (pt) | Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| BRPI0907898B8 (pt) | antagonistas do receptor da melanocortina-5 3-substituído-1, 4-diazepan-2-ona | |
| MX2010009488A (es) | Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor. | |
| EA201170672A1 (ru) | Соединения, пригодные для лечения целлюлита | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |